Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

The new authorisation has been granted for a single-dose, pre-filled pen device that requires ... when compared with Bydureon and Eli Lilly’s Trulicity. Market analysts suggest that Novo Nordisk ...

Saxenda – which comes as prefilled self-injection pen – will be used as part ... Ozempic is squaring off in the market against Eli Lilly’s Trulicity (dulaglutide), which grew 22% to $3. ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...

In 2025, Lilly also expects an unfavorable impact from foreign exchange rates on the top line. Sales of Trulicity are likely to have been hurt by competitive dynamics and lower realized prices in ...

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

Pharmaceutical company Eli Lilly announced promising clinical trial results this week for a daily pill to treat obesity and diabetes. Besides the good news of minimal side effects and impressive ...